Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.3%

3 terminated/withdrawn out of 70 trials

Success Rate

93.5%

+7.0% vs industry average

Late-Stage Pipeline

14%

10 trials in Phase 3/4

Results Transparency

1 of 43 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

34(54.8%)

Phase 2

9(14.5%)

N/A

8(12.9%)

Phase 3

6(9.7%)

Phase 4

4(6.5%)

Early Phase 1

1(1.6%)

62Total

Phase 1(34)

Phase 2(9)

N/A(8)

Phase 3(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (70)

Showing 20 of 70 trials

NCT07396844Phase 1Not Yet Recruiting

The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers

Role: lead

NCT06495281Completed

Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients

Role: lead

NCT07399470Phase 1Active Not Recruiting

A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.

Role: lead

NCT07333742Phase 1Completed

A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal

Role: lead

NCT03934099Phase 2Completed

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

Role: lead

NCT06332755Phase 1Recruiting

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

Role: lead

NCT05586958Phase 3Completed

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

Role: lead

NCT05586971Phase 3Completed

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Role: lead

NCT06947499Phase 2Recruiting

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

Role: lead

NCT06743997Phase 1Completed

A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability

Role: lead

NCT06921395Phase 4Recruiting

Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).

Role: lead

NCT05431933Phase 3Completed

Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants

Role: lead

NCT04855188Not ApplicableCompleted

Effectiveness and Safety of YVOIRE Y-Solution 540

Role: lead

NCT05314504Not ApplicableCompleted

Clinical Investigation of YVOIRE Y-Solution 360 for Lip Augmentation in China

Role: lead

NCT04784299Not ApplicableCompleted

To Evaluate the Performance and Safety of YVOIRE Volume Plus for Improvement of Mid-face Volume

Role: lead

NCT06618196Phase 2Not Yet Recruiting

Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age